Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Current Deferred Revenue (2024 - 2025)

BioRestorative Therapies (BRTX) has disclosed Current Deferred Revenue for 4 consecutive years, with $150000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Current Deferred Revenue changed N/A year-over-year to $150000.0, compared with a TTM value of $150000.0 through Mar 2025, changed N/A, and an annual FY2014 reading of $164349.0, changed N/A over the prior year.
  • Current Deferred Revenue was $150000.0 for Q1 2025 at BioRestorative Therapies, up from $80700.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $150000.0 in Q1 2025 and bottomed at $80700.0 in Q2 2024.